TG Therapeutics | TGTX - Operating Expenses


TG Therapeutics reported $218.66M in Operating Expenses for its fiscal quarter ending in June of 2026.





Operating Expenses Change Date
AbbVie USD 10.27B 1000K Jun/2026
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Amgen USD 11.69B 6.9B Jun/2026
Ardelyx USD 127.27M 7.15M Mar/2026
Arrowhead Research USD 215M 8.23M Mar/2026
Bayer EUR 9.88B 452M Mar/2026
Biogen USD 2.98B 1.02B Jun/2026
Corcept Therapeutics USD 214.85M 343K Jun/2026
Curis USD 11.52M 2.5M Mar/2026
Gilead Sciences USD 3.95B 19.57B Jun/2026
J&J USD 17.83B 388M Jun/2026
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Novartis USD 10.2B 912M Jun/2026
Novavax USD 126.2M 23.62M Dec/2025
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Regeneron Pharmaceuticals USD 31.71B 287.8M Jun/2026
Roche Holding CHF 18.9B 2.12B Jun/2026
TG Therapeutics USD 218.66M 48.54M Jun/2026
Verastem USD 63.57M 4.56M Mar/2026
Vertex Pharmaceuticals USD 2.07B 217.1M Jun/2026